Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Shares of Moderna Inc. MRNA, -3.59% gained 0.1% on Friday after the company said it is now developing mRNA vaccines for herpes simplex virus, varicella-zoster virus (against shingles), and certain types of cancer, starting with advanced or metastatic melanoma and non-small cell lung carcinoma. The company's stock is down 13.7% over the past year, while the broader S&P 500 SPX, -2.12% is 11.4%.

Moderna to develop three new mRNA vaccine candidates

mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV) mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce the rate of herpes zoster (shingles) mRNA-4359 is a new checkpoint cancer vaccine CAMBRIDGE, MA / ACCESSWIRE / February 18, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its mRNA pipeline with three new development programs. This announcement reflects the Company's commitment to expanding its portfolio building on Moderna's experience with Spikevax®, its COVID-19 vaccine.

Moderna Expands Its mRNA Pipeline with Three New Development Programs

Moderna Inc's (NASDAQ: MRNA) CEO, Stephane Bancel, told Reuters that an omicron-specific booster could be ready by August. The CEO said that the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab.

Moderna Says COVID-19 Booster To Be Ready By August, But Dicey If Omicron-Specific Needed: Reuters

Pfizer

Pfizer's billion-dollar mRNA vaccine could be just the beginning.

2 Reasons Why Pfizer Might Crush Moderna in the mRNA Market. And 1 Reason Why Moderna May Stay Ahead.

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

They're already bringing in billions of dollars in revenue.

3 Top Biotech Stocks to Buy for the Long Haul

CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 µg dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. "The TGA authorization for the use of our COVID-19 vaccine in children 6-11 years old in Australia is an important milestone for Moderna as it is the first regulatory authorization for the use of our vaccine in this age group.

Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)

Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region Local commercial presence to be established in Belgium, Denmark, the Netherlands, Norway, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across six additional countries in Europe. Moderna plans to establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally.

Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries

CEO Stephane Bancel says he thinks the end of the Covid-19 pandemic is a 'reasonable scenario.'

Moderna CEO Says End of Pandemic Is Nearing

Moderna stock has declined by almost 40% thus far in 2022 and currently trades at about $142 per share. The sell-off is driven by a couple of factors.

At $140, Moderna Stock Is A Solid Value Bet

Spain's Laboratorios Farmaceuticos Rovi SA has agreed on a 10-year extension to its deal with Moderna Inc (NASDAQ: MRNA) to manufacture future drugs developed with the mRNA technology used for its COVID-19 shot. The new agreement includes a series of investments expected to increase manufacturing capacity across ROVI's facilities in Madrid, Spain.

Moderna-Rovi Seal 10-Year Deal Extension To Make mRNA Drugs

Stéphane Bancel believes there's about an 80% chance that the virus causing COVID-19 will get less virulent, but cautioned it remains "unpredictable."

Moderna's CEO says it's 'reasonable' to suggest the COVID-19 pandemic is in its final stages

The tide has turned for this once high-flying vaccine stock.

Why It's Time to Buy Moderna Stock Again

Moderna CEO Says End of Covid-19 Pandemic Is Approaching

“I think that's a reasonable scenario.”

Key Words: The end of the pandemic may be in sight, says Moderna CEO

"I think that is a reasonable scenario," Moderna's CEO Stephane Bancel said when asked about the whether the Covid-19 pandemic may now be in its final stages.

Moderna CEO says it's ‘reasonable' to think pandemic may be in its final stages

Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain CAMBRIDGE, MA and MADRID, SPAIN / ACCESSWIRE / February 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI's facilities, located in Madrid, San Sebastián de los Reyes and Alcalá de Henares.

Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years

Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong; providing local presence to support the delivery of mRNA vaccines and therapeutics CAMBRIDGE, MA / ACCESSWIRE / February 15, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine and future mRNA vaccines and therapeutics.

Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries

Wall Street lower on Monday as geopolitical tensions between Russia and Ukraine intensified.

Stock Market News for Feb 15, 2022

US drugmaker Moderna Therapeutics Inc (NASDAQ:MRNA) is closing in on a deal with the UK government to open a vaccine research and manufacturing centre. The company, which makes the mRNA Coronavirus (COVID-19) jab, was originally in talks to buy an existing research and manufacturing hub in Oxford but has veered away from the idea.

Moderna in talks with UK government over vaccine research and manufacturing hub

One of last year's best-performing stocks, Moderna has plummeted more than 70% from its all-time high six months ago.

Moderna Stock Crash: Losses Top $140 Billion As Insiders Sell Millions Of Dollars In Shares

Moderna Inc. MRNA shares are trading lower Monday. A recent CDC study showed protection from COVID-19 booster doses can wane after four months.

Moderna Continues To See Bearish Movement: What's Next For The COVID-19 Stock?

Moderna dropped more than 12%, the biggest decline in the S&P 500 as of Monday afternoon.

Moderna, Pfizer stocks fall as omicron Covid wave subsides in U.S.

Here's where the expert Wall Street analysts think Moderna and MRNA stock could be headed from here, following recent weakness. The post Is MRNA Stock a Buy Following 12% Plunge?

Is MRNA Stock a Buy Following 12% Plunge? 5 Analysts Weigh In.

Moderna Inc (NASDAQ:MRNA) is down 12.3% at $141.52 this afternoon, following reports that the firm's CEO Stephane Barncel sold 10,000 shares of its stock, amounting to roughly $1.8 million.

News for Moderna Stock (MRNA)